A study published earlier this year has demonstrated chronic administration of 5-Caffeoylquinic Acid (5-CQA) to be effective in reducing Aβ deposition in the APP/PS2 AD mouse model, improving cognitive deficits and neuronal functions: 5-CQA normalised AQP4 perivascular mislocalisation and increased Aβ clearance along the glymphatic system [72], reiterating the importance of AQP4 in this clearance system. Here, APP is linked to Alzheimer disease.